{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T19:39:59Z","timestamp":1784057999387,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1097\/maj.0b013e3181ff2393","type":"journal-article","created":{"date-parts":[[2011,1,13]],"date-time":"2011-01-13T08:46:02Z","timestamp":1294908362000},"page":"185-190","source":"Crossref","is-referenced-by-count":8,"title":["Influence of Predictive Modeling in Implementing Optimal Heart Failure Therapy"],"prefix":"10.1016","volume":"341","author":[{"given":"Hari","family":"Prasad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaspinder","family":"Sra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwight D.","family":"Stapleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne C.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0005","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/0002-8703(93)90738-U","article-title":"Epidemiology of heart failure in the United States","volume":"126","author":"Gillum","year":"1993","journal-title":"Am Heart J"},{"issue":"suppl A","key":"10.1097\/MAJ.0b013e3181ff2393_bb0010","first-page":"3A","article-title":"Heart failure in the 1990s: evolution of a major public health problem in cardiovascular medicine. J Am Coll Cardiol","volume":"22","author":"Garg","year":"1993"},{"issue":"suppl 4","key":"10.1097\/MAJ.0b013e3181ff2393_bb0015","first-page":"S107","article-title":"Economic impact of heart failure in the United States: time for a different approach","volume":"13","author":"O\u2019Connell","year":"1994","journal-title":"J Heart Lung Transplant"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0020","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/clc.4960190319","article-title":"Cost-effective management of heart failure","volume":"19","author":"Parmley","year":"1996","journal-title":"Clin Cardiol"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0025","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0030","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","article-title":"A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure","volume":"325","author":"Cohn","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0035","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/fampra\/9.3.362","article-title":"Selections from current literature: treatment of congestive heart failure with angiotensin converting enzyme inhibitors","volume":"9","author":"Bowers","year":"1992","journal-title":"Fam Pract"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0040","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/0140-6736(93)91937-H","article-title":"Clinical trials and clinical practice [editorial]","volume":"342","year":"1993","journal-title":"Lancet"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0045","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1136\/bmj.308.6942.1488","article-title":"Implementing the findings of research","volume":"308","author":"Haines","year":"1994","journal-title":"BMJ"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0050","first-page":"A14","article-title":"Transferring evidence from research into practice: overcoming barriers to application","volume":"126","author":"Haynes","year":"1997","journal-title":"ACP J Club"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0055","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/oxfordjournals.eurheartj.a059896","article-title":"Validity of clinical diagnosis of heart failure in primary health care","volume":"12","author":"Remes","year":"1991","journal-title":"Eur Heart J"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0060","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/hrt.71.6.584","article-title":"Evidence of inadequate investigation and treatment of patients with heart failure","volume":"71","author":"Clarke","year":"1994","journal-title":"Br Heart J"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0065","first-page":"278","article-title":"Failure to treat heart failure [editorial]. Lancet","volume":"339","year":"1992"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0070","first-page":"77","article-title":"Prevalence, etiology and management of heart failure in general practice","volume":"46","author":"Mair","year":"1996","journal-title":"Br J Gen Pract"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0075","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1161\/CIRCULATIONAHA.105.584102","article-title":"The Seattle Heart Failure Model: prediction of survival in heart failure","volume":"113","author":"Levy","year":"2006","journal-title":"Circulation"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0080","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/(SICI)1099-1557(199809\/10)7:5<331::AID-PDS365>3.0.CO;2-B","article-title":"The use of angiotensin converting enzyme inhibitors in general practice\u2014appropriate or inappropriate?","volume":"7","author":"Connolly","year":"1998","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0085","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/0735-1097(95)80020-H","article-title":"Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure","volume":"26","author":"Dickstein","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0090","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1136\/bmj.317.7169.1352","article-title":"Initiating angiotensin converting enzyme inhibitors in mild to moderate heart failure in general practice: randomized, placebo controlled trial","volume":"317","author":"Lough","year":"1998","journal-title":"BMJ"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0095","first-page":"21","article-title":"Implications of the ATLAS study for clinical practice","volume":"100","author":"Packer","year":"1999","journal-title":"Int J Clin Pract Suppl"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0100","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS study group","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0105","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0110","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/oxfordjournals.eurheartj.a015297","article-title":"Effects of beta-blocker therapy on mortality in patients with heart failure\u2014systematic overview of randomized controlled trials","volume":"18","author":"Doughty","year":"1997","journal-title":"Eur Heart J"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0115","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0735-1097(97)00104-6","article-title":"Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized trials","volume":"30","author":"Heidenreich","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0120","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1136\/bmj.318.7187.824","article-title":"The evidence for \u03b2-blockers in heart failure. Equals or surpasses that for angiotensin converting enzyme inhibitors","volume":"318","author":"Cleland","year":"1999","journal-title":"BMJ"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0125","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0002-9149(96)00465-1","article-title":"Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])","volume":"78","author":"Investigators","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0130","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1011119003788","article-title":"The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction: Eplerenone Post-AMI Heart Failure Efficacy and Survival Study","volume":"15","author":"Pitt","year":"2001","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0135","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/CIRCULATIONAHA.104.527549","article-title":"Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001","volume":"112","author":"Masoudi","year":"2005","journal-title":"Circulation"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0140","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1001\/jama.2009.1493","article-title":"Use of aldosterone antagonists in heart failure","volume":"302","author":"Albert","year":"2009","journal-title":"JAMA"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0145","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0150","unstructured":"A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines (EMPHASIS-HF). Available at: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00232180?term= heart+failure&rank=1. Accessed November 10, 2010."},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0155","first-page":"1383","article-title":"Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0160","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.106.174516","article-title":"AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute","volume":"113","author":"Smith","year":"2006","journal-title":"Circulation"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0165","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0170","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa043399","article-title":"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure","volume":"352","author":"Bardy","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0175","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.jacc.2005.09.016","article-title":"Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) Trial","volume":"46","author":"Carson","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0180","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","article-title":"Cardiac-resynchronization therapy for the prevention of heart-failure events","volume":"361","author":"Moss","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0185","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2008.11.013","volume":"53","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0190","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial","volume":"353","author":"CIBIS Investigators","year":"1999","journal-title":"Lancet"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0195","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3181ff2393_bb0200","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","article-title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure inthe Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial","volume":"362","author":"Poole-Wilson","year":"2003","journal-title":"Lancet"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915313410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915313410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T20:19:43Z","timestamp":1559938783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962915313410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0002962915313410"],"URL":"https:\/\/doi.org\/10.1097\/maj.0b013e3181ff2393","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}